Multiple CpG oligodeoxynucleotides and their use to induce...

Details Multiple CpG oligodeoxynucleotides and their use to induce... Multiple CpG oligodeoxynucleotides and their use to induce...

2011-04-05

2011-04-05

Minnifield, N. M (Department: 1645)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S278100

Reexamination Certificate

active

07919477

ABSTRACT:
Compositions including multiple oligodeoxynucleotides with a CpG motif are disclosed herein. The compositions can include either D or K type oligodeoxynucleotides. These compositions are of use in inducing an immune response in a large percentage of the individuals in a population.

REFERENCES:
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 5023243 (1991-06-01), Tullis
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 6194388 (2001-02-01), Krieg et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6214806 (2001-04-01), Krieg et al.
patent: 6218371 (2001-04-01), Krieg et al.
patent: 6239116 (2001-05-01), Krieg et al.
patent: 6339068 (2002-01-01), Krieg et al.
patent: 6406705 (2002-06-01), Davis et al.
patent: 6423539 (2002-07-01), Fong et al.
patent: 6428788 (2002-08-01), Debinski et al.
patent: 6429199 (2002-08-01), Krieg et al.
patent: 6498148 (2002-12-01), Raz
patent: 6514948 (2003-02-01), Raz et al.
patent: 6534062 (2003-03-01), Raz et al.
patent: 6552006 (2003-04-01), Raz et al.
patent: 6562798 (2003-05-01), Schwartz
patent: 6589940 (2003-07-01), Raz et al.
patent: 6610661 (2003-08-01), Carson et al.
patent: 6613751 (2003-09-01), Raz et al.
patent: 6653292 (2003-11-01), Krieg et al.
patent: 6949520 (2005-09-01), Hartmann et al.
patent: 6977245 (2005-12-01), Klinman et al.
patent: 7615227 (2009-11-01), Klinman et al.
patent: 7666674 (2010-02-01), Klinman et al.
patent: 7758876 (2010-07-01), Klinman et al.
patent: 7776344 (2010-08-01), Hartmann et al.
patent: 2001/0034330 (2001-10-01), Kensil
patent: 2001/0036462 (2001-11-01), Fong et al.
patent: 2001/0044416 (2001-11-01), McCluskie et al.
patent: 2001/0046967 (2001-11-01), Van Nest
patent: 2002/0006403 (2002-01-01), Yu et al.
patent: 2002/0028784 (2002-03-01), Van Nest
patent: 2002/0042383 (2002-04-01), Yew et al.
patent: 2002/0042387 (2002-04-01), Raz et al.
patent: 2002/0055477 (2002-05-01), Van Nest et al.
patent: 2002/0064515 (2002-05-01), Krieg et al.
patent: 2002/0065236 (2002-05-01), Yew et al.
patent: 2002/0086295 (2002-07-01), Raz et al.
patent: 2002/0086839 (2002-07-01), Raz et al.
patent: 2002/0090724 (2002-07-01), Taylor et al.
patent: 2002/0091095 (2002-07-01), Phillips et al.
patent: 2002/0091097 (2002-07-01), Bratzler et al.
patent: 2004/0052763 (2004-03-01), Mond et al.
patent: 2007/0202575 (2007-08-01), Klinman et al.
patent: 2009/0263405 (2009-10-01), Verthelyi et al.
patent: 2010/0113565 (2010-05-01), Gorden et al.
patent: 2010/0226941 (2010-09-01), Klinman et al.
patent: 0 468 520 (1991-01-01), None
patent: 0 092 574 (1992-04-01), None
patent: 0 572 735 (1993-12-01), None
patent: 0 855 184 (1998-07-01), None
patent: 1 198 249 (2002-04-01), None
patent: WO 92/18522 (1992-10-01), None
patent: WO 93/17115 (1993-09-01), None
patent: WO 94/19945 (1994-09-01), None
patent: WO 95/18231 (1995-07-01), None
patent: WO 95/26204 (1995-10-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 97/28259 (1997-08-01), None
patent: WO 98/11211 (1998-03-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 98/49288 (1998-11-01), None
patent: WO 98/52581 (1998-11-01), None
patent: WO 98/55495 (1998-12-01), None
patent: WO 99/11275 (1999-03-01), None
patent: WO 99/51259 (1999-10-01), None
patent: WO 99/56755 (1999-11-01), None
patent: WO 99/58118 (1999-11-01), None
patent: WO 99/61056 (1999-12-01), None
patent: WO 99/62923 (1999-12-01), None
patent: WO 00/06588 (2000-02-01), None
patent: WO 00/20039 (2000-04-01), None
patent: WO 00/21556 (2000-04-01), None
patent: WO 00/61151 (2000-10-01), None
patent: WO 00/62787 (2000-10-01), None
patent: WO 00/67023 (2000-11-01), None
patent: WO 01/00232 (2001-01-01), None
patent: WO 01/02007 (2001-01-01), None
patent: WO 01/12223 (2001-02-01), None
patent: WO 01/22990 (2001-04-01), None
patent: WO 01/51500 (2001-07-01), None
patent: WO 01/55341 (2001-08-01), None
patent: WO 01/68077 (2001-09-01), None
patent: WO 01/68103 (2001-09-01), None
patent: WO 01/68116 (2001-09-01), None
patent: WO 01/68117 (2001-09-01), None
U.S. Appl. No. 60/209,797.
U.S. Appl. No. 60/128,898.
Alama et al., “Antisense Oligonucleotides as Therapeutic Agents,”Pharmacol. Res. 36: 171-178 (1997).
Anfossi, et al., “An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines”. Proc. Natl. Acad. Sci. USA 86:3379-3383 (1989).
Ballas, et al., “Induction of NK Activity in Murine and Human Cells by CpG Motifs in Oligodeoxynucleotides and Bacterial DNA,”J. Immun. 157: 1840-1845 (1996).
Bauer, et al., “Bacterial CpG-DNA Triggers Activation and Maturation of Human CD11c-, CD123+ Dendritic Cells”. J. Immunol. 166:5000-5007 (2001).
Benimetskaya, et al., “Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kBp65) ‘antisense’ oligodeoxynucleotide”. Nucleic Acids Research 25(13):2648-2656 (1997).
Boggs, et al., “Characterization and modulation of immune stimulation by modified oligonucleotides”. Antisense Nucl. Acid Drug Dev. 7(5):461-471 (1997).
Branda, et al., “Amplification of antibody production by phosphorothioate oligodeoxynucleotides”. J. Lab Clin. Med. 128(3):329-338 (1996).
Chu, et al., “CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity”. J. Exp. Med. 186(10):1623-1631 (1997).
Deml, et al., “Immunostimulatory CpG motifs trigger a T Helper-1 immune response to Human Immunodeficiency Virus Type-1 (HIV-1) gp160 envelope protein”. Clin. Chem. Lab. Med. 37(3):199-204 (1999).
Gao, et al., “Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and Rnase H: Implications for antisense technology”. Mol. Pharmacol. 41:223-229 (1992).
Gursel, et al., “Differential and Competitive Activation of Human Immune Cells by Distinct Classes of CpG Oligodeoxynucleotide”. J. Leuko. Biol. 71:813-820 (2002).
Halpern, et al., “Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha”. Cell Immunol. 167(1):72-78 (1996).
Ishibashi, et al., “Sp1 Decoy Transfected to Carcinoma Cells Suppresses the Expression of Vascular Endothelial Growth Factor, Transforming Growth Factor β, and Tissue Factor and Also Cell Growth and Invasion Activities”. Cancer Research 60:6531-6536 (2000).
Iversen, et al., “Pharmacokinetics of an antisense phosphorothioate oigodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single inections and continuous infusion”. Antisense Res. Dev. 4:43-52 (1994).
Jilek, et al., “Antigen-Independent Suppression of the Allergic Immune Response to Bee Venom Phospholipase A2 by DNA Vaccination in CBA/J Mice”. J. Immunol. 166:3612-3621 (2001).
Kadowaki, et al., “Distinct CpG DNA and Polyinosinic-Polycytidylic Acid Double Stranded RNA, Respectively, Stimulate CD11c- Type 2 Dendritic Cell Precursoes and CD11c+ Dendritic cells to Produce Type I IFN”. J. Immunol. 166:2291-2295 (2001).
Klinman, et al., “CpG Motifs Present in Bacterial DNA Rapidly Induce Lymphocytes to Secrete Interleukin 6, Interleukin 12 and Interferon γ,”Proc. Natl. Acad. Sci. USA93: 2879-2883 (1996).
Klinman, et al., “CpG Motifs as Immune Adjuvants,”Vaccine17: 19-25 (1999).
Klinman, et al., “Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety”. Springer Semin. Immunopathol. 22:173-183 (2000).
Krieg, et al., “CpG motifs in bacterial DNA and their immune effect”. Annu. Rev. Immunol. 20:709-760 (2002).
Krieg, et al., “Brief Communication: Oligodeoxynucleotide Modifications Determine the Magnitude of B-Cell Stimulation by CpG Motifs”. Antisense & Nucleic Acid Drug Development 6:133-139 (1996).
Krieg, et al., “Leukocyte stimulation by oligod

Affiliated with

Also associated with

Rating

Multiple CpG oligodeoxynucleotides and their use to induce... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Multiple CpG oligodeoxynucleotides and their use to induce..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multiple CpG oligodeoxynucleotides and their use to induce... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2731662